Literature DB >> 12228184

Flavin-containing monooxygenase activity in hepatocytes and microsomes: in vitro characterization and in vivo scaling of benzydamine clearance.

Michael B Fisher1, Kwansik Yoon, Marcie L Vaughn, Timothy J Strelevitz, Robert S Foti.   

Abstract

Liver microsomes, and more recently cryopreserved hepatocytes, are commonly used in the in vitro characterization of the metabolism of new xenobiotics. The flavin-containing monooxygenases (FMO) are a major non p450 oxidase present in liver microsomes and hepatocytes. Since FMO is known to be thermally labile, and this enzyme may be involved in the metabolic clearance of some drugs, we sought to more completely characterize the metabolic competency of this enzyme in cryopreserved hepatocytes and in liver microsomes preincubated under various conditions using benzydamine as an in vitro and in vivo probe. The metabolism of benzydamine to its major metabolite, the N-oxide, is mediated by FMO3 in humans. We found that the in vitro microsomal t(1/2) was 70% longer when incubations were prewarmed at 37 degrees C in the absence of NADPH compared with prewarming in the presence of an NADPH-regenerating system, and N-oxide formation was inhibited >99%. Interestingly, the in vivo clearance predicted from these incubations and from human hepatocytes overpredicted the observed clearance of benzydamine in humans (>10.5 versus 2.4 ml/min/kg). In contrast, rat hepatocytes successfully predicted rat in vivo benzydamine clearance to within approximately 30% (>68 versus 48 ml/min/kg). Benzydamine N-oxidation in liver microsomes from all common preclinical species demonstrated heat sensitivity. This information should be considered when extrapolating metabolism data of xenobiotics from these in vitro systems.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12228184     DOI: 10.1124/dmd.30.10.1087

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  4 in total

1.  Metabolic Profiling of Human Long-Term Liver Models and Hepatic Clearance Predictions from In Vitro Data Using Nonlinear Mixed-Effects Modeling.

Authors:  Nicole A Kratochwil; Christophe Meille; Stephen Fowler; Florian Klammers; Aynur Ekiciler; Birgit Molitor; Sandrine Simon; Isabelle Walter; Claudia McGinnis; Johanna Walther; Brian Leonard; Miriam Triyatni; Hassan Javanbakht; Christoph Funk; Franz Schuler; Thierry Lavé; Neil J Parrott
Journal:  AAPS J       Date:  2017-01-03       Impact factor: 4.009

Review 2.  Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.

Authors:  Enoch Cobbina; Fatemeh Akhlaghi
Journal:  Drug Metab Rev       Date:  2017-03-17       Impact factor: 4.518

3.  Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes.

Authors:  Souzan B Yanni; Pieter P Annaert; Patrick Augustijns; Arlene Bridges; Yan Gao; Daniel K Benjamin; Dhiren R Thakker
Journal:  Drug Metab Dispos       Date:  2008-03-24       Impact factor: 3.922

4.  Influence of Proteome Profiles and Intracellular Drug Exposure on Differences in CYP Activity in Donor-Matched Human Liver Microsomes and Hepatocytes.

Authors:  Christine Wegler; Pär Matsson; Veronica Krogstad; Jozef Urdzik; Hege Christensen; Tommy B Andersson; Per Artursson
Journal:  Mol Pharm       Date:  2021-03-19       Impact factor: 4.939

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.